Literature DB >> 9768711

Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction. Investigators of this Multicenter Study.

J Meluzín1, J Cerný, M Frélich, F Stetka, L Spinarová, J Popelová, R Stípal.   

Abstract

OBJECTIVES: The purpose of our study was to assess the prognostic importance of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease (CAD) and left ventricular (LV) dysfunction.
BACKGROUND: The amount of dysfunctional but viable myocardium predicts the functional improvement after revascularization and may offer more precise risk stratification of patients referred for bypass surgery or coronary angioplasty.
METHODS: Two hundred and seventy-four consecutive patients with CAD and LV ejection fraction < or =40% underwent low-dose dobutamine echocardiography for viability assessment. One hundred and thirty-three of them were revascularized using either coronary artery bypass surgery (118 patients) or coronary angioplasty (15 patients) and entered this study. To quantify the amount of dysfunctional but viable myocardium, wall motion was scored using 16-segment model. The dysfunctional segments were defined as viable if they exhibited improvement in their thickening by at least 1 grade with dobutamine infusion. The patients were followed up for a mean period of 20+/-12 months (range, 2 to 48) for cardiac mortality and nonfatal cardiac events including myocardial infarction, unstable angina pectoris requiring hospitalization and hospitalization for heart failure. Standard follow-up echocardiography was performed 3 to 6 months after revascularization.
RESULTS: Twenty-nine patients exhibited a large amount of dysfunctional but viable myocardium (> or =6 segments, group A), 60 patients had a small amount of dysfunctional but viable myocardium (2 to 5 segments, group B) and 44 patients were found to have dysfunctional myocardium irreversibly damaged (group C). Similar prerevascularization LV ejection fractions of 35%+/-5%, 34%+/-4%, 36%+/-4% in groups A, B and C increased to 47%+/-6% (p < 0.01 vs. baseline, p < 0.01 vs. groups B and C), to 40%+/-5% (p < 0.01 vs. baseline) and to 37%+/-6% (p = NS vs baseline), respectively, after revascularization. The greatest functional improvement after revascularization in group A patients was accompanied by a lower rate of cardiac events during follow-up (2 vs. 18 in group B, p < 0.05, and vs. 17 in group C, p < 0.01) and better cardiac event-free survival according to Kaplan-Meier survival analysis (p < 0.05 vs. groups B and C, respectively).
CONCLUSION: In revascularized patients with CAD and moderate or severe LV dysfunction, the presence of a large amount of dysfunctional but viable myocardium identifies patients with the best prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9768711     DOI: 10.1016/s0735-1097(98)00324-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  41 in total

Review 1.  Pathophysiology of myocardial hibernation. Implications for the use of dobutamine echocardiography to identify myocardial viability.

Authors:  J L Vanoverschelde; A Pasquet; B Gerber; J A Melin
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

Review 2.  Surgical alternatives to transplantation and assist devices in the treatment of heart failure.

Authors:  J J DeRose; M C Oz
Journal:  Curr Cardiol Rep       Date:  2000-11       Impact factor: 2.931

3.  Usefulness of distinct activity thresholds according to baseline regional asynergy for predicting functional recovery in patients with chronic coronary artery disease and left ventricular dysfunction: a study with nitrate-enhanced sestamibi gated SPECT.

Authors:  M Leoncini; G Marcucci; R Sciagrà; F Frascarelli; F Bellandi; M Gallopin; A Mennuti; R P Dabizzi
Journal:  J Nucl Cardiol       Date:  2001 Sep-Oct       Impact factor: 5.952

Review 4.  Stress echocardiography.

Authors:  Thomas H Marwick
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

Review 5.  Radionuclide techniques for the assessment of myocardial viability and hibernation.

Authors:  J J Bax; E E van der Wall; M Harbinson
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 6.  Current and future role of cardiovascular magnetic resonance in cardiac resynchronization therapy.

Authors:  Francisco Leyva; Paul W X Foley
Journal:  Heart Fail Rev       Date:  2011-05       Impact factor: 4.214

Review 7.  Stress echocardiography for the diagnosis and risk stratification of patients with suspected or known coronary artery disease: a critical appraisal. Supported by the British Society of Echocardiography.

Authors:  R Senior; M Monaghan; H Becher; J Mayet; P Nihoyannopoulos
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

8.  Low-dose dobutamine nitrate-enhanced technetium 99m sestamibi gated SPECT versus low-dose dobutamine echocardiography for detecting reversible dysfunction in ischemic cardiomyopathy.

Authors:  Mario Leoncini; Roberto Sciagrà; Francesco Bellandi; Mauro Maioli; Stelvio Sestini; Gabriella Marcucci; Angela Coppola; Fabio Frascarelli; Alberto Mennuti; Roberto P Dabizzi
Journal:  J Nucl Cardiol       Date:  2002 Jul-Aug       Impact factor: 5.952

9.  Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET.

Authors:  Riemer H J A Slart; Jeroen J Bax; Dirk J van Veldhuisen; Ernst E van der Wall; Rudi A Dierckx; Jaep de Boer; Pieter L Jager
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

10.  Low dose wall motion score predicts the short and long-term benefit of surgical revascularization in patients with ischemic left ventricular dysfunction.

Authors:  Yasir Abdul Ghaffar; Waddah Maskoun; Nowwar G Mustafa; Harvey Feigenbaum; Stephen G Sawada
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-03       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.